TICKERNERD
Menu
EIKNHealthcare · Biotechnology

EIKN Stock Forecast: Eikon Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$11
+5.77% on the day

The 6 Wall Street analysts covering Eikon Therapeutics, Inc. hold a median 12-month price target of $29 — +155.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 2 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$616.9M
Ticker Nerd rank
2 / 100
Median analyst target
$29
Analysts covering
6
Total return, dividends reinvested
1W
+2.9%
1M
+14.7%
From high
−30.1%
From low
+36.0%
$8
$16
Range since 5 Feb 2026, adjusted closes · the dot is the last close
Ticker Nerd rank

EIKN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Eikon Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
2 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
52
Size
51
Momentum
8
Growth
8
Accruals
8
Value
7
Quality
2
Issuance
2
Volatility
1

Revisions (52): Analysts have, on balance, been raising their forecasts.

Volatility (1): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

EIKN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on EIKN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 5 Feb 2026Adjusted close, US dollars
$0$5$10$15$20$25$30$35Mar 26Apr 26May 26Jun 26Jul 26Aug 26EIKNHigh $32Median $29Low $4

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says6 analysts
5 Buy0 Hold1 Sell
Low $4Median $29High $32

The green dot is the last close — the median target sits +155.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
14 Aug 2026WedbushMaintainsUnderperform$5.00 → $4.00
12 May 2026WedbushMaintainsUnderperform—
12 May 2026WedbushMaintainsUnderperform$7.00 → $5.00
31 Mar 2026WedbushReiteratesUnderperform—
2 Mar 2026B of A SecuritiesInitiatesBuy—
2 Mar 2026Cantor FitzgeraldInitiatesOverweight—
2 Mar 2026JP MorganInitiatesOverweight—
2 Mar 2026MizuhoInitiatesOutperform—
2 Mar 2026Morgan StanleyInitiatesOverweight—
26 Feb 2026WedbushInitiatesUnderperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. EIKN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

EIKN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
2
Fundamentals

Eikon Therapeutics, Inc. (EIKN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.8×

Cheaper than 85% of US stocks

Price / sales
—
Price / book
1.3×

Cheaper than 63% of US stocks

EV / EBITDA
−1.1×

Cheaper than 67% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
38.0%

Higher than 91% of US stocks

Return on assets
−56.1%

Higher than 7% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

EIKN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
EIKNEikon Therapeutics, Inc.$616.9M
2
PRMEPrime Medicine, Inc.$614.9M
33
OABIOmniAb, Inc.$623.3M
93
SGMTSagimet Biosciences, Inc.$627.1M
31
VSTMVerastem, Inc.$605.2M
58
ALTAltimmune, Inc.$604.4M
23
ARVNArvinas, Inc.$601.5M
84

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Eikon Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest EIKN news & analysis

Eikon Therapeutics Eyes Safer PARP1 Cancer Treatments With EIK1003, EIK1004

MarketBeat · 22 Aug 2026neutral

Eikon Therapeutics outlined its development strategy for the selective PARP1 inhibitors EIK1003 and EIK1004 and its Werner helicase inhibitor during a discussion hosted by Cantor analyst Imogen Mansfield. CEO Roger Perlmutter and MD Anderson's Tim Yap discussed the rationale for improving on earlier PARP inhibitor therapies, which typically inhibit both PARP1 and PARP2.

Why it matters — The update details the progress and rationale behind Eikon's cancer pipeline for PARP1-selective programs, giving EIKN watchers insight into the company's development focus.

Eikon Therapeutics, Inc. (EIKN) Discusses Advances in PARP1 Biology and Next-Generation PARP Inhibitors in Oncology Transcript

Seeking Alpha · 22 Aug 2026neutral

Eikon Therapeutics, Inc. (EIKN) participated in a discussion, presented as a transcript, covering advances in PARP1 biology and next-generation PARP inhibitors in oncology. The item reports on this discussion without providing additional detail.

Why it matters — A EIKN watcher would care because it highlights the company's ongoing work in the PARP inhibitor space, a key area of its oncology research and development pipeline.

Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald

GlobeNewsWire · 18 Aug 2026neutral

Eikon Therapeutics announced that its Chairman and CEO, Roger M. Perlmutter, M.D., Ph.D., will participate in a key opinion leader (KOL) event on the therapeutic use of PARP inhibitors in oncology, hosted by Cantor Fitzgerald on Thursday, August 20, 2026.

Why it matters — The CEO's participation in a Cantor-hosted oncology KOL event gives EIKN watchers an opportunity to hear the company's leadership discuss therapeutic applications of PARP inhibitors relevant to its pipeline.

Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

GlobeNewsWire · 13 Aug 2026neutral

Eikon Therapeutics reported its second quarter 2026 financial results and provided updates on its clinical programs. The company, a late-stage clinical biopharmaceutical firm, released the information via a press announcement dated August 13, 2026.

Why it matters — The report offers EIKN watchers the company's latest financial standing and progress across its clinical pipeline.

Eikon Therapeutics Appoints Johnny Bennett, Ph.D. to its Scientific Advisory Board

GlobeNewsWire · 10 Aug 2026positive

Eikon Therapeutics announced the appointment of Johnny Bennett, Ph.D. to its Scientific Advisory Board. The company, a late-stage clinical biopharmaceutical firm, made the announcement on August 10, 2026.

Why it matters — A new scientific advisory board member could bring additional expertise to Eikon's late-stage clinical development efforts, which may be of interest to those tracking the company's scientific leadership.

FAQ

Frequently asked questions about EIKN stock

What is the EIKN stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Eikon Therapeutics, Inc. have a median 12-month price target of $29, with estimates ranging from $4 to $32. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is EIKN stock a buy right now?

Of the 6 analysts covering Eikon Therapeutics, Inc., 5 rate it a Buy, 0 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Eikon Therapeutics, Inc. 2 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank EIKN?

As at 22 Aug 2026, Eikon Therapeutics, Inc. ranks 2 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (52 of 100).

Will EIKN stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +155.1% from the last close, and Ticker Nerd's factor model ranks Eikon Therapeutics, Inc. 2 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the EIKN stock forecast for 2030?

No analyst covering Eikon Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EIKN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $32 over the next 12 months.

What does Eikon Therapeutics, Inc. do?

Eikon Therapeutics, Inc. is a late-stage clinical biopharmaceutical company pioneering advanced drug discovery through visualization of protein motion in living cells.

What is the latest news on EIKN?

The most recent item we track (MarketBeat, 22 Aug 2026): "Eikon Therapeutics Eyes Safer PARP1 Cancer Treatments With EIK1003, EIK1004". Eikon Therapeutics outlined its development strategy for the selective PARP1 inhibitors EIK1003 and EIK1004 and its Werner helicase inhibitor during a discussion hosted by Cantor analyst Imogen Mansfield. CEO Roger Perlmutter and MD Anderson's Tim Yap discussed the rationale for improving on earlier PARP inhibitor therapies, which typically inhibit both PARP1 and PARP2.

Company

About Eikon Therapeutics, Inc.

Eikon Therapeutics, Inc. is a late-stage clinical biopharmaceutical company pioneering advanced drug discovery through visualization of protein motion in living cells. Founded in 2019 and headquartered in Millbrae, California, it employs 384 people and focuses on developing therapies primarily for cancer treatment using innovative imaging techniques. The company integrates cutting-edge technology to observe dynamic protein behaviors, aiming to revolutionize how drugs are identified and optimized for oncology indications. Key leadership includes CEO Roger Perlmutter, co-founders Xavier Darzacq, Robert Tjian, and Eric Betzig, alongside experts like Chief Scientific Officer Dan Anderson and Chief Medical Officer Roy Baynes. Supported by prominent investors such as T. Rowe Price, Lux Capital, General Catalyst, and Foresite Capital, Eikon Therapeutics has raised substantial funding through multiple rounds, including a $351 million Series B in 2025. Operating in the biological products sector, it plays a significant role in advancing precision medicine for challenging diseases.

CEO Dr. Roger M. Perlmutter M.D., Ph.D. · 384 employees · United States · https://eikontx.com